Pharma Giant Paid ‘Elite’ Obesity Specialists $25.8 Million to Promote Weight Loss Drugs
Despite the drugs’ serious side effects — including major gastrointestinal issues, self-harm behaviors and cancers — the Association of American Pediatrics recommends the drugs in its new clinical guidelines, the American Medical Association urges insurance carriers to cover the drugs, and the mainstream and medical press heavily promote them.
⬇️
https://childrenshealthdefense.org/defender/novo-nordisk-obesity-drugs-paid-specialists-promotion/?utm_source=sovren&utm_medium=social&utm_campaign=defender&utm_id=20231208
An “elite” and influential group of obesity specialists over the last decade pocketed at least $25.8 million in payments from Novo Nordisk, maker of weight loss drugs Wegovy and Saxenda, in exchange for promoting the drugs in their lectures, treatment guidelines, clinics and medical societies, according to an investigation by Reuters.
childrenshealthdefense.org
0
Share on Telegram
Share on Facebook
Share on Twitter
Share on Reddit